Replies to post #171 on Alkermes, Inc. (ALKS)

[Serenity3]

Bravo FDA ... challenging efficacy not just rubber stamping ALKS new drug idea to market another bottle of miracle cure... looking at ALL phase 3 not just the ones that showed statistically significant results that the company said validated their drug... companies are notorious for choosing the studies that validate their thesis and dropping the ones that don't...oh and the CEO's breathless comment on the CC call yesterday that there have been no pharmacological advances for major depression for the past 30 years as a reason for the FDA to rush another drug to market belies the fact that studies have shown that medication and CBT therapy are equally effective after 6 months but that CBT effectiveness lasts years after completion while medication effectiveness diminishes rapidly after the medication is stopped .. as for pharmacological interventions.. take a look at this link form UCSD on alternatives ... https://health.ucsd.edu/news/features/Pages/2018-01-03-q-and-a-ketamine-for-depression.aspx